Treatment-related mortality overall during 17 years, during the first decade and thereafter
| . | 1994-2011 (n = 522) . | 1994-2003 (n = 310) . | 2004-2011 (n = 212) . | P value (during 1st decade and thereafter) . |
|---|---|---|---|---|
| TRM events (%) | 61 (12%) | 52 (17%) | 9 (4%) | .000012 |
| Median age (range) | 56 (35-78) | 55 (35-78) | 62 (53-69) | |
| During SCMC | 11 (2%) | 10 (3%) | 1 (0.5%) | .032 |
| Cardiac events | 8 (73%) | 7 (70%) | 1 (100%) | |
| Hemorrhagic events | 2 (18%) | 2 (20%) | 0 (0%) | |
| Respiratory events | 1 (9%) | 1 (10%) | 0 (0%) | |
| During SCT | 4 (1%) | 3 (1%) | 1 (0.5%) | .65 |
| Cardiac events | 3 (75%) | 2 (67%) | 1 (100%) | |
| Pulmonary embolism | 1 (25%) | 1 (33%) | 0 (0%) | |
| After SCT | 46 (9%) | 39 (13%) | 7 (3%) | .0002 |
| Infections | 22 (48%) | 18 (46%) | 4 (57%) | |
| Bacterial | 11 | 9 | 2 | |
| Fungal | 9 | 7 | 2 | |
| Viral | 2 | 2 | 0 | |
| Cardiac events | 17 (37%) | 15 (39%) | 2 (29%) | |
| Hemorrhagic events | 5 (11%) | 4 (10%) | 1 (14%) | |
| Respiratory events | 3 (7%) | 3 (7%) | 0 (0%) | |
| Other events | 2 (4%) | 2 (5%) | 0 (0%) | |
| Disease pattern | ||||
| > 2 organ involvement | 54 (89%) | 49 (94%) | 5 (56%) | .007 |
| Cardiac involvement | 53 (87%) | 45 (87%) | 8 (89%) | .99 |
| Dose of melphalan | ||||
| 100 mg/m2 | 6 | 6 | 0 | |
| 140 mg/m2 | 20 | 16 | 4 | |
| 200 mg/m2 | 24 | 20 | 4 | |
| Serum Creatinine > 2mg/dL | 10 (16%) | 7 (13%) | 3 (33%) | .157 |
| . | 1994-2011 (n = 522) . | 1994-2003 (n = 310) . | 2004-2011 (n = 212) . | P value (during 1st decade and thereafter) . |
|---|---|---|---|---|
| TRM events (%) | 61 (12%) | 52 (17%) | 9 (4%) | .000012 |
| Median age (range) | 56 (35-78) | 55 (35-78) | 62 (53-69) | |
| During SCMC | 11 (2%) | 10 (3%) | 1 (0.5%) | .032 |
| Cardiac events | 8 (73%) | 7 (70%) | 1 (100%) | |
| Hemorrhagic events | 2 (18%) | 2 (20%) | 0 (0%) | |
| Respiratory events | 1 (9%) | 1 (10%) | 0 (0%) | |
| During SCT | 4 (1%) | 3 (1%) | 1 (0.5%) | .65 |
| Cardiac events | 3 (75%) | 2 (67%) | 1 (100%) | |
| Pulmonary embolism | 1 (25%) | 1 (33%) | 0 (0%) | |
| After SCT | 46 (9%) | 39 (13%) | 7 (3%) | .0002 |
| Infections | 22 (48%) | 18 (46%) | 4 (57%) | |
| Bacterial | 11 | 9 | 2 | |
| Fungal | 9 | 7 | 2 | |
| Viral | 2 | 2 | 0 | |
| Cardiac events | 17 (37%) | 15 (39%) | 2 (29%) | |
| Hemorrhagic events | 5 (11%) | 4 (10%) | 1 (14%) | |
| Respiratory events | 3 (7%) | 3 (7%) | 0 (0%) | |
| Other events | 2 (4%) | 2 (5%) | 0 (0%) | |
| Disease pattern | ||||
| > 2 organ involvement | 54 (89%) | 49 (94%) | 5 (56%) | .007 |
| Cardiac involvement | 53 (87%) | 45 (87%) | 8 (89%) | .99 |
| Dose of melphalan | ||||
| 100 mg/m2 | 6 | 6 | 0 | |
| 140 mg/m2 | 20 | 16 | 4 | |
| 200 mg/m2 | 24 | 20 | 4 | |
| Serum Creatinine > 2mg/dL | 10 (16%) | 7 (13%) | 3 (33%) | .157 |
TRM indicates treatment-related mortality; SCMC, stem cell mobilization and collection; and SCT, stem cell transplantation.